http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
-
Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
-
Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
-
GUINNESS WORLD RECORDS™ Title Achieved for Organ Donor Registrations
-
Astellas Oncology Selects Five C3 Prize™ Finalists to Pitch Ideas for Changing Cancer Care to Panel Including Robert Herjavec at Stanford Medicine X
-
Astellas Oncology Selects Five C3 Prize™ Finalists to Pitch Ideas for Changing Cancer Care to Panel Including Robert Herjavec at Stanford Medicine X
-
Astellas Oncology Announces Data to be Presented at 2016 ASCO Annual Meeting
-
Astellas Oncology C3 Prize™ to Bring Bright Ideas in Cancer Care to Life with $100,000 in Grants
-
Astellas Names James Robinson President, Americas Operations
-
Astellas and Medivation (MDVN) Announces STRIVE Trial Results Published in Journal of Clinical Oncology
-
Journal of Clinical Oncology Publishes Results From the STRIVE Trial of Enzalutamide Compared to Bicalutamide in Castration-Resistant Prostate Cancer
-
Journal of Clinical Oncology Publishes Results from the STRIVE trial of enzalutamide Compared to bicalutamide in Castration-resistant Prostate Cancer
-
Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of Enzalutamide Compared to Bicalutamide in Metastatic Castration-Resistant Prostate Cancer
-
Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of enzalutamide Compared to bicalutamide in Metastatic Castration-Resistant Prostate Cancer
-
Astellas Agrees to PGA TOUR Sponsorship through 2020
-
Astellas Announces Updated Data from the Phase 1/2 CHRYSALIS Trial for Gilteritinib (ASP2215) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
-
Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan
-
Astellas Announces New Data to be Presented at the 2015 ASH Annual Meeting
-
Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award
-
New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting
-
Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML)
-
Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
-
Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be Presented at 2015 ASCO Annual Meeting
-
Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting
-
Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics

